此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估吸烟对单次口服GS1-144片后药代动力学的影响。

一项药物-药物相互作用研究,旨在评估吸烟(CYP1A2诱导剂)对中国健康绝经后女性试验参与者单次口服GS1-144片剂后药代动力学的影响

A Drug-Drug Interaction Study to Evaluate the Effect of Smoking (CYP1A2 Inducer) on the Pharmacokinetics Following a Single Oral Dose of GS1-144 Tablets in Chinese Healthy Postmenopausal Female Trial Participants

研究概览

地位

完全的

条件

详细说明

This drug-drug interaction study adopts an open-label, parallel design to evaluate the effect of smoking on the PK following a single oral dose of GS1-144 tablets in Chinese healthy postmenopausal female trial participants.

研究类型

介入性

注册 (实际的)

24

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Jinan
      • Shandong、Jinan、中国、100021
        • The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria:

1)40 to 65 years of age (inclusive) at the time of signing the informed consent form (ICF).

2)Trial participants are healthy females who meet any of the following criteria during screening:

  1. Consecutive spontaneous amenorrhea ≥ 12 months.

  2. Consecutive spontaneous amenorrhea ≥ 6 months but < 12 months, with serum follicle-stimulating hormone (FSH) levels > 40 IU/L.

  3. ≥ 6 weeks after bilateral oophorectomy.

  4. History of hysterectomy with preservation of one or both ovaries and FSH levels > 40 IU/L.

    3)Body weight ≥ 45 kg, and body mass index (BMI) within the range of 18-28 kg/m2 (inclusive).

    4)Able to communicate well with the investigator, understand and comply with all study requirements, voluntarily agree to participate in the trial, and understand and voluntarily sign the ICF.

    5)Smoker:smoking ≥ 10 cigarettes per day within 6 months prior to screening, and urinary cotinine level ≥ 1,000 ng/mL at screening. Smokers will be required to continue smoking in designated areas according to their habits during the study.

    6)Non-smoker: no smoking within 6 months prior to screening, and urinary cotinine level < 200 ng/mL at screening.

    Exclusion Criteria:

    1. Known history of hypersensitivity to the investigational drug, any of its excipients, or related formulations; or a history of allergic disorders (including but not limited to asthma, urticaria); or being allergy-prone (e.g., known allergy to two or more substances).
    2. History or current diagnosis of diseases of the circulatory, digestive, urinary, respiratory, endocrine and metabolic, hematological and lymphatic, immune, psychiatric and neurological, or dermatological systems, and deemed unsuitable for participation by the investigator.
    3. History of severe infection, serious trauma, or major surgery within 6 months prior to screening, or planning to undergo surgery during the trial.
    4. Blood donation or blood loss ≥ 400 mL, or receipt of blood transfusion within 3 months prior to screening, or planning to donate blood within 1 month after the end of the trial.
    5. Use of any prescription medications [including but not limited to drugs known to alter hepatic enzyme activity (e.g., glucocorticoids, sex hormones, anticonvulsants, cyclosporine)] within 4 weeks prior to screening, or use of any over-the-counter (OTC) medications (including but not limited to herbal medicines, herbal compound prescriptions, health supplements) or vitamin supplements within 2 weeks prior to screening.
    6. Trial participants with abnormal findings in physical examination, chest X-ray, abdominal and urinary ultrasound, genital ultrasound, thyroid and parathyroid ultrasound, or laboratory tests at screening, which are deemed unsuitable for participation by the investigator.
    7. During screening or on D-1, any of the following liver function test results as follows: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 1.5 × upper limit of normal (ULN), or total bilirubin (TBIL) ≥ 1.2 × ULN.
    8. Abnormal vital signs and deemed unsuitable for participation by the investigator, or systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg during screening.
    9. Abnormal 12-lead ECG findings and deemed unsuitable for participation by the investigator, or QTcF > 470 ms (Fridericia's formula: QTcF = QT/RR0.33, RR = 60/heart rate) during screening.
    10. Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TP-Ab) during screening.
    11. Participation in another clinical trial within 3 months prior to screening (except for trial participants who did not receive any investigational intervention), or current participation in any other clinical trial.
    12. Current or past history of drug abuse within 1 year, or positive urine multi-drug test panel.
    13. Positive alcohol breath test or history of excessive alcohol consumption (defined as >14 units of alcohol per week) within 3 months prior to screening (One standard alcohol unit is equivalent to 17.5 mL or 14 g of pure ethanol. Alcohol content is labeled by volume (ABV) for all beverage types. This corresponds approximately to 35 mL of 50% spirits or 350 mL of 5% beer), or unwillingness to abstain from alcohol or any alcohol-containing products during the trial.
    14. Consumption of food or beverages that may affect drug metabolism (e.g., containing grapefruit, starfruit, or their products) within 48 hours prior to admission.
    15. Excessive consumption of tea, coffee, or caffeinated beverages (>8 cups per day, 1 cup=250 mL) within 3 months prior to screening; or consumption of any food or beverage containing or metabolized to caffeine or xanthine (e.g., coffee, tea, chocolate, cola) within 24 hours prior to admission.
    16. Pregnant or lactating women, or those who have a clinically significant positive pregnancy test result.
    17. Poor venous access, a history of difficult venipuncture, intolerance to venipuncture/intravenous indwelling needle, or needle/blood phobia.
    18. Other conditions deemed unsuitable by the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:GS1-144 片剂

All trial participants will receive the investigational drug (GS1-144 tablets) at a dose of 30 mg.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
GS1-144的主要药代动力学参数:Cmax。
大体时间:最长72小时
最长72小时
GS1-144的主要药代动力学参数:AUC0-t。
大体时间:长达72小时
长达72小时
GS1-144的主要药代动力学参数:AUC0-∞。
大体时间:最长可达 72 小时
最长可达 72 小时
GS1-144的次要药代动力学参数:Tmax。
大体时间:长达72小时
长达72小时
GS1-144的次要药代动力学参数:消除速率常数(λz)。
大体时间:长达72小时
长达72小时
GS1-144的次要药代动力学参数:t1/2。
大体时间:长达72小时
长达72小时
GS1-144的次要药代动力学参数:CL/F。
大体时间:最长72小时
最长72小时
GS1-144的次要药代动力学参数:Vd/F。
大体时间:最多72小时
最多72小时
GS1-144的次要药代动力学参数:AUC_%Extrap。
大体时间:长达72小时
长达72小时

次要结果测量

结果测量
大体时间
主要代谢物M1的PK参数:Cmax。
大体时间:最长72小时
最长72小时
主要代谢物 M1 的 PK 参数:AUC0-t。
大体时间:长达72小时
长达72小时
主要代谢物M1的药代动力学参数:AUC0-∞。
大体时间:最多72小时
最多72小时
主要代谢物M1的药代动力学参数:Tmax。
大体时间:长达72小时
长达72小时
主要代谢物M1的PK参数:λz。
大体时间:最多 72 小时
最多 72 小时
主要代谢物 M1 的药代动力学参数:t1/2。
大体时间:最长72小时
最长72小时
主要代谢物M1的PK参数:AUC_%Extrap。
大体时间:最长72小时
最长72小时
不良事件(AEs)。
大体时间:长达72小时
长达72小时

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月20日

初级完成 (实际的)

2026年7月2日

研究完成 (实际的)

2026年7月29日

研究注册日期

首次提交

2026年3月25日

首先提交符合 QC 标准的

2026年4月15日

首次发布 (实际的)

2026年4月16日

研究记录更新

最后更新发布 (实际的)

2026年9月18日

上次提交的符合 QC 标准的更新

2026年9月15日

最后验证

2026年3月1日

更多信息

与本研究相关的术语

其他研究编号

  • GenSci074-107

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅